BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 14967416)

  • 1. Secretion of tissue plasminogen activator and plasminogen activator inhibitor 1 during cardiopulmonary bypass.
    Chandler WL; Velan T
    Thromb Res; 2003; 112(3):185-92. PubMed ID: 14967416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The kinetics of plasmin inhibition by aprotinin in vivo.
    Kang HM; Kalnoski MH; Frederick M; Chandler WL
    Thromb Res; 2005; 115(4):327-40. PubMed ID: 15668193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass.
    Chandler WL; Fitch JC; Wall MH; Verrier ED; Cochran RP; Soltow LO; Spiess D
    Thromb Haemost; 1995 Nov; 74(5):1293-7. PubMed ID: 8607112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A kinetic model of the circulatory regulation of tissue plasminogen activator during orthotopic liver transplantation.
    Crookston KP; Marsh CL; Chandler WL
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):79-88. PubMed ID: 10691102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A kinetic model of the circulatory regulation of tissue plasminogen activator.
    Chandler WL
    Thromb Haemost; 1991 Sep; 66(3):321-8. PubMed ID: 1746003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass.
    Pretorius M; Murphey LJ; McFarlane JA; Vaughan DE; Brown NJ
    Circulation; 2003 Dec; 108(25):3079-83. PubMed ID: 14656921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiopulmonary bypass parameters and hemostatic response to cardiopulmonary bypass in infants versus children.
    Eisses MJ; Chandler WL
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):53-9. PubMed ID: 18249331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
    Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
    Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy.
    Lu H; Du Buit C; Soria J; Touchot B; Chollet B; Commin PL; Conseiller C; Echter E; Soria C
    Thromb Haemost; 1994 Sep; 72(3):438-43. PubMed ID: 7531877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury.
    Matsuno H; Kozawa O; Niwa M; Ueshima S; Matsuo O; Collen D; Uematsu T
    Thromb Haemost; 1999 Apr; 81(4):601-4. PubMed ID: 10235447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states.
    Niwano H; Takahashi H; Tatewaki W; Wada K; Seki Y; Shibata A
    Blood Coagul Fibrinolysis; 1992 Aug; 3(4):389-93. PubMed ID: 1420814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor activity is associated with raised lactate levels after cardiac surgery with cardiopulmonary bypass.
    Dixon B; Santamaria JD; Campbell DJ
    Crit Care Med; 2003 Apr; 31(4):1053-9. PubMed ID: 12682472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective double-arm study of fibrinolysis in surgical patients.
    Kosir MA; Schmittinger L; Barno-Winarski L; Duddella P; Pone M; Perales A; Lange P; Brish LK; McGee K; Beleski K; Pawlak J; Mammen E; Sajahan NP; Kozol RA
    J Surg Res; 1998 Jan; 74(1):96-101. PubMed ID: 9536981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Tisseel on expression of tissue plasminogen activator and plasminogen activator inhibitor-1.
    Diamond MP; Kruger M; Saed GM
    Fertil Steril; 2004 Jun; 81(6):1657-64. PubMed ID: 15193491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
    Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK
    Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fluctuations of tissue-type plasminogen activator.plasminogen activator inhibitor-1 complex in patients with DIC].
    Nagaizumi K; Kuroso K; Amano K; Sato T; Fukutake K; Fujimaki M
    Rinsho Byori; 1994 Jul; 42(7):707-12. PubMed ID: 8065036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: dependence on stent implantation and antithrombotic medication.
    Christ G; Nikfardjam M; Huber-Beckmann R; Gottsauner-Wolf M; Glogar D; Binder BR; Wojta J; Huber K
    J Thromb Haemost; 2005 Feb; 3(2):233-9. PubMed ID: 15670026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in hemostasis during pediatric heart surgery: impact of a biocompatible heparin-coated perfusion system.
    Jensen E; Andréasson S; Bengtsson A; Berggren H; Ekroth R; Larsson LE; Ouchterlony J
    Ann Thorac Surg; 2004 Mar; 77(3):962-7. PubMed ID: 14992907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activator inhibitor-1 is the primary inhibitor of tissue-type plasminogen activator in pregnancy plasma.
    Jørgensen M; Philips M; Thorsen S; Selmer J; Zeuthen J
    Thromb Haemost; 1987 Oct; 58(3):872-8. PubMed ID: 3124286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute endothelial tissue plasminogen activator release in pregnancy.
    Robb AO; Mills NL; Din JN; Cameron S; Ludlam CA; Newby DE; Denison FC
    J Thromb Haemost; 2009 Jan; 7(1):138-42. PubMed ID: 18983502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.